The European Commission has approved atezolizumab for use in combination with carboplatin and etoposide for the frontline treatment of adult patients with extensive-stage small cell lung cancer, according to Roche (Genentech) the developer of the PD-L1 inhibitor.
Steven T. Rosen, MD, discusses the rapid evolution in hematologic cancer treatment and highlighted challenges that have recently emerged.
Manish Patel, DO, discusses advances and remaining questions with chemoimmunotherapy combinations in nonsquamous metastatic non–small cell lung cancer.
Experts from City of Hope share insight on some of the pivotal research being conducted at their institution.
The combination of nivolumab plus standard temozolomide and radiation therapy did not show a statistically significant improvement in progression-free survival compared with temozolomide/radiation therapy alone in patients with newly diagnosed glioblastoma multiforme that is O6-methylguanine-DNA methyltransferase-methylated, missing one of the primary endpoints of the phase III CheckMate-548 trial.
Amrita Krishnan, MD, highlights recent research in relapsed/refractory multiple myeloma.
Sipuleucel-T (Provenge) was associated with a median overall survival of 47.7 months in a subgroup of patients with asymptomatic or minimally invasive metastatic castration-resistant prostate cancer.
Risk-reducing therapies, such as tamoxifen, raloxifene, or aromatase inhibitors, should be administered to women who are at an increased risk for breast cancer and at a low risk for adverse events associated with these medications.
The FDA has granted a breakthrough therapy designation to the investigational gamma-secretase inhibitor nirogacestat (PF-03084014) for the treatment of adult patients with progressive, unresectable, recurrent or refractory desmoid tumors or deep fibromatosis.
Petros Grivas, MD, highlights the evolving role of immunotherapy in bladder cancer and ongoing research slated to further progress along.
Alexander Drilon, MD, provides insight into his study on the role of larotrectinib in the treatment of patients with TRK fusions and brain metastases or those with primary CNS disease.
The European Commission has approved the combination of pembrolizumab (Keytruda) and axitinib (Inlyta) for the frontline treatment of patients with advanced renal cell carcinoma.
China’s National Medical Products Administration has approved osimertinib for the frontline treatment of adult patients with locally-advanced or metastatic non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions or exon 21 (L858R) substitutions.
The FDA has granted an orphan drug designation to neratinib (Nerlynx) for the treatment of patients with breast cancer who have brain metastases.
Michael A. Rosenzweig, MD, MS, discusses changes in the frontline setting of multiple myeloma.
David S. Snyder, MD, highlights agents currently undergoing clinical trials for polycythemia vera and myelofibrosis as well as how to most effectively treat patients using transplantation.
Poziotinib is being tested in a biomarker-driven trial of patients with non–small cell lung cancer in both second-line and treatment-naïve settings.
Encorafenib (Braftovi) plus binimetinib (Mektovi) had superior overall survival and progression-free survival compared with encorafenib or vemurafenib (Zelboraf) alone in patients with BRAF V600–mutant melanoma.
The tumor-infiltrating lymphocyte therapy LN-145 induced promising response rates with acceptable safety in patients with recurrent, metastatic, or persistent cervical cancer—a patient population of great unmet need.
The FDA has extended the review period for a supplemental biologics license application for atezolizumab for use in combination with carboplatin and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer who do not have EGFR or ALK aberrations.
A cluster of clinical news in biosimilars has been announced over the last few days, with pooled data sets against reference products, an expected launch of a novel study, and a cost efficiency analysis.
The triplet regimen of vorinostat (Zolinza), cladribine, and rituximab (Rituxan) demonstrated an objective response rate of 97% and a complete response rate of 80% in newly diagnosed patients with mantle cell lymphoma.
Rebecca C. Arend, MD, discusses several ongoing trials exploring the use of immunotherapy in patients with advanced ovarian cancer.
Samir Parekh, MBBS, highlights ongoing research regarding personalized medicine for multiple myeloma.
Camille C. Gunderson, MD, discusses the various maintenance options available in advanced ovarian cancer, as well as what factors should be considered for selecting each approach.
Hearn Jay Cho, MD, PhD, provides background on these novel approaches, while highlighting exciting trials to look for in the future.
The combination of the off-the-shelf cancer immune primer ilixadencel and sunitinib elicited a 11% complete response rate in patients with metastatic renal cell carcinoma, according to topline findings from the phase II MERECA trial (NCT02432846).
Patients with differentiated thyroid cancer who were felt to not have a choice in receiving radioactive iodine treatment reportedly had lower satisfaction with the treatment decision, suggesting a need for increased shared decision making between physicians and patients.
Robert M. Rifkin, MD, FACP, discusses details of bringing biosimilars to market, ongoing challenges, and the need for education of these products.
AbbVie has officially ended its rovalpituzumab tesirine (Rova-T) research and development program, which was exploring the antibody-drug conjugate in patients with small cell lung cancer.
